Zynerba Press Releases

14 Sep 20 Zynerba Pharmaceuticals Provides Update on Recent Milestones

10 Sep 20 Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

10 Aug 20 Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights

6 Aug 20 Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference

22 Jul 20 Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup

30 Jun 20 Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

27 May 20 Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder

26 May 20 Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

26 May 20 Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

22 May 20 Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference